LEERINK PARTNERS

A CPE Exclusive: Attruby™ for Transthyretin Amyloid Cardiomyopathy



Published on: November 26, 2024

> The U.S. Food and Drug Administration approved acoramidis (Attruby™, BridgeBio Pharma, Inc.) on November 22nd, 2024. A Leerink Center for Pharmacoeconomics (CPE) Exclusive shows Attruby's societal value exceeds its US price even under conservative assumptions.

GCEA shows Attruby's societal value exceeds its US price even under conservative assumptions.

The market-based price for Attruby is less than the benefit it will provide society. This is supported by our generalized cost-effectiveness analysis (GCEA) that followed recent best practices to assess the societal impact of a treatment over the product's expected time in the market. Findings from our GCEA suggest that if accounting for expected future price dynamics, Attruby will benefit society long after its "high" price.

Check out our full report to understand the specific impact Attruby may have on each domain of value, how it may perform under conventional and generalized cost-effectiveness analysis frameworks, and why our estimates are likely conservative.

The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners

Leerink Center for Pharmacoeconomics

- Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics

Contributors:

Melanie Whittington

Center for Pharmacoeconomics

Disclosures:

This information (including, but not limited to, prices, quotes, and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and the information and any opinions contained herein are as of the date of this material and the Firm does not undertake any obligation to update them. The information is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC ("Firm"), its officers, directors, employees, proprietary accounts, and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this piece. The Firm's research analysts, bankers, salespeople, and traders may provide oral or written market commentary or trading strategies that are contrary to opinions expressed, and the Firm's market making desk may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. This material does not take into account individual circumstances, objectives, or needs and is not intended as a recommendation to any particular person(s). As such, the financial instruments discussed herein may not be suitable for all investors, and investors must make their own investment decisions based upon their specific investment objectives and financial situation. This material is a marketing communication and is not and should not be construed as investment research or a research report prepared by a research analyst. Any views portrayed in this material may differ from those of the research department of Leerink Partners LLC. All information contained herein is intended solely for your own personal, informational use, and you are not permitted to reproduce, retransmit, disseminate, sell, license, distribute, republish, broadcast, post, circulate or commercially exploit the information in any manner or media without the express written consent of Leerink Partners LLC, or to use the information for any unlawful purpose. Additional information is available upon request by contacting the Editorial Department, Leerink Partners LLC, 53 State Street, 40th Floor, Boston, MA 02109.MEDACorp LLC (MEDACorp), an affiliate of Leerink Partners LLC, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients.
Member FINRA/SIPC